Literature DB >> 10323325

Drug-induced immunotoxicity.

P M Dansette1, E Bonierbale, C Minoletti, P H Beaune, D Pessayre, D Mansuy.   

Abstract

Immune-related drug responses are one of the most common sources of idiosyncratic toxicity. A number of organs may be the target of such reactions; however, this review concentrates mostly on the liver. Drug-induced hepatitis is generally divided into two categories: acute hepatitis in which the drug or a metabolite destroys a vital target in the cell; immunoallergic hepatitis in which the drug triggers an adverse immune response directed against the liver. Their clinical features are: a) low frequency; b) dose independence; c) typical immune system manifestations such as fever, eosinophilia; d) delay between the initiation of treatment and onset of the disease; e) a shortened delay upon rechallenge; and f) occasional presence of autoantibodies in the serum of patients. Such signs have been found in cases of hepatitis triggered by drugs such as halothane, tienilic acid, dihydralazine and anticonvulsants. They will be taken as examples to demonstrate the recent progress made in determining the mechanisms responsible for the disease. The following mechanisms have been postulated: 1) the drug is first metabolized into a reactive metabolite which binds to the enzyme that generated it; 2) this produces a neoantigen which, once presented to the immune system, might trigger an immune response characterized by 3) the production of antibodies recognizing both the native and/or the modified protein; 4) rechallenge leads to increased neoantigen production, a situation in which the presence of antibodies may induce cytolysis. Toxicity is related to the nature and amount of neoantigen and also to other factors such as the individual immune system. An effort should be made to better understand the precise mechanisms underlying this kind of disease and thereby identify the drugs at risk; and also the neoantigen processes necessary for their introduction into the immune system. An animal model would be useful in this regard.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10323325     DOI: 10.1007/BF03189993

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  62 in total

1.  Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase.

Authors:  H Satoh; B M Martin; A H Schulick; D D Christ; J G Kenna; L R Pohl
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

2.  Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation.

Authors:  A J Munns; J J De Voss; W D Hooper; R G Dickinson; E M Gillam
Journal:  Chem Res Toxicol       Date:  1997-09       Impact factor: 3.739

3.  Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro.

Authors:  D K Spracklin; D C Hankins; J M Fisher; K E Thummel; E D Kharasch
Journal:  J Pharmacol Exp Ther       Date:  1997-04       Impact factor: 4.030

4.  Immune mechanisms in tienilic acid associated hepatotoxicity.

Authors:  J Neuberger; R Williams
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

5.  Lymphocyte stimulation induced by halothane in patients with hepatitis following exposure to halothane.

Authors:  F Paronetto; H Popper
Journal:  N Engl J Med       Date:  1970-08-06       Impact factor: 91.245

6.  Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9.

Authors:  S Lecoeur; C André; P H Beaune
Journal:  Mol Pharmacol       Date:  1996-08       Impact factor: 4.436

7.  Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B.

Authors:  C Pons; P M Dansette; J Gregeois; J C Homberg; E E Billett; D Mansuy
Journal:  Biochem Biophys Res Commun       Date:  1996-01-05       Impact factor: 3.575

8.  Controlled prospective study of the effect on liver function of multiple exposures to halothane.

Authors:  R Wright; O E Eade; M Chisholm; M Hawksley; B Lloyd; T M Moles; J C Edwards; M J GArdner
Journal:  Lancet       Date:  1975-04-12       Impact factor: 79.321

9.  Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: specificity of autoantibodies and inductive capacity of the drug.

Authors:  M Bourdi; J C Gautier; J Mircheva; D Larrey; A Guillouzo; C Andre; C Belloc; P H Beaune
Journal:  Mol Pharmacol       Date:  1992-08       Impact factor: 4.436

10.  Pentahaloethane-based chlorofluorocarbon substitutes and halothane: correlation of in vivo hepatic protein trifluoroacetylation and urinary trifluoroacetic acid excretion with calculated enthalpies of activation.

Authors:  J W Harris; J P Jones; J L Martin; A C LaRosa; M J Olson; L R Pohl; M W Anders
Journal:  Chem Res Toxicol       Date:  1992 Sep-Oct       Impact factor: 3.739

View more
  10 in total

Review 1.  Mechanisms of drug toxicity and relevance to pharmaceutical development.

Authors:  F Peter Guengerich
Journal:  Drug Metab Pharmacokinet       Date:  2010-10-22       Impact factor: 3.614

Review 2.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 3.  Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.

Authors:  Sung-Mi Kim; YongQiang Wang; Noushin Nabavi; Yi Liu; Maria Almira Correia
Journal:  Drug Metab Rev       Date:  2016-06-20       Impact factor: 4.518

4.  Design, synthesis, and structure-activity relationship studies of thiophene-3-carboxamide derivatives as dual inhibitors of the c-Jun N-terminal kinase.

Authors:  Surya K De; Elisa Barile; Vida Chen; John L Stebbins; Jason F Cellitti; Thomas Machleidt; Coby B Carlson; Li Yang; Russell Dahl; Maurizio Pellecchia
Journal:  Bioorg Med Chem       Date:  2011-03-12       Impact factor: 3.641

Review 5.  Drug-induced autoimmune-like hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-02-16       Impact factor: 3.487

Review 6.  Drug Induced Liver Injury: Review with a Focus on Genetic Factors, Tissue Diagnosis, and Treatment Options.

Authors:  Tawfik Khoury; Ayman Abu Rmeileh; Liron Yosha; Ariel A Benson; Saleh Daher; Meir Mizrahi
Journal:  J Clin Transl Hepatol       Date:  2015-06-15

7.  Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.

Authors:  Julie Massart; Karima Begriche; Caroline Moreau; Bernard Fromenty
Journal:  J Clin Transl Res       Date:  2017-02-12

Review 8.  Goitrogenic and estrogenic activity of soy isoflavones.

Authors:  Daniel R Doerge; Daniel M Sheehan
Journal:  Environ Health Perspect       Date:  2002-06       Impact factor: 9.031

9.  Scaffold hopping and optimisation of 3',4'-dihydroxyphenyl- containing thienopyrimidinones: synthesis of quinazolinone derivatives as novel allosteric inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H.

Authors:  Graziella Tocco; Francesca Esposito; Pierluigi Caboni; Antonio Laus; John A Beutler; Jennifer A Wilson; Angela Corona; Stuart F J Le Grice; Enzo Tramontano
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

10.  Humanized Mouse as a Tool to Predict Immunotoxicity of Human Biologics.

Authors:  Kylie Su Mei Yong; Zhisheng Her; Sue Yee Tan; Wilson Wei Sheng Tan; Min Liu; Fritz Lai; Shi Min Heng; Yong Fan; Kenneth Tou En Chang; Cheng-I Wang; Jerry Kok Yen Chan; Jianzhu Chen; Qingfeng Chen
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.